Article: Future prevention and treatment of chronic hepatitis B infection

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleFuture prevention and treatment of chronic hepatitis B infection
AuthorsSeto, WK1
Fung, J1
Yuen, MF1
Lai, CL1
Keywordsbesifovir
FG-3019
HELIPSAV
interferon-λ
REP 9AC
vaccination
Issue Date2012
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
CitationJournal Of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734 [How to Cite?]
DOI: http://dx.doi.org/10.1097/MCG.0b013e3182610191
AbstractVaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement. Several patient populations are noted to have suboptimal seroprotective rates after HBV vaccination. There are currently several potential new vaccines undergoing animal and human studies, most notably vaccines containing immunostimulatory DNA sequences. Long-term nucleoside analogue therapy is necessary in achieving permanent virologic suppression. Potential new treatments explore new mechanisms of action, including the inhibition of hepatitis B surface antigen release, targeting antifibrotic mechanism, and immunomodulation through novel interferons and therapeutic vaccines. The clinical application of potential new vaccines and therapies would enhance the prevention of HBV infection and treatment of chronic hepatitis B. © 2012 by Lippincott Williams & Wilkins.
ISSN0192-0790
2011 Impact Factor: 3.159
2011 SCImago Journal Rankings: 0.260
DOIhttp://dx.doi.org/10.1097/MCG.0b013e3182610191
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorSeto, WK
dc.contributor.authorFung, J
dc.contributor.authorYuen, MF
dc.contributor.authorLai, CL
dc.date.accessioned2012-09-20T07:58:12Z
dc.date.available2012-09-20T07:58:12Z
dc.date.issued2012
dc.description.abstractVaccination for hepatitis B virus (HBV) infection and treatment for chronic hepatitis B, while effective for primary prevention and control of the disease, still have their limitations. Global coverage of HBV immunization needs improvement. Several patient populations are noted to have suboptimal seroprotective rates after HBV vaccination. There are currently several potential new vaccines undergoing animal and human studies, most notably vaccines containing immunostimulatory DNA sequences. Long-term nucleoside analogue therapy is necessary in achieving permanent virologic suppression. Potential new treatments explore new mechanisms of action, including the inhibition of hepatitis B surface antigen release, targeting antifibrotic mechanism, and immunomodulation through novel interferons and therapeutic vaccines. The clinical application of potential new vaccines and therapies would enhance the prevention of HBV infection and treatment of chronic hepatitis B. © 2012 by Lippincott Williams & Wilkins.
dc.description.natureLink_to_subscribed_fulltext
dc.identifier.citationJournal Of Clinical Gastroenterology, 2012, v. 46 n. 9, p. 725-734 [How to Cite?]
DOI: http://dx.doi.org/10.1097/MCG.0b013e3182610191
dc.identifier.doihttp://dx.doi.org/10.1097/MCG.0b013e3182610191
dc.identifier.epage734
dc.identifier.hkuros210584
dc.identifier.issn0192-0790
2011 Impact Factor: 3.159
2011 SCImago Journal Rankings: 0.260
dc.identifier.issue9
dc.identifier.scopuseid_2-s2.0-84866240582
dc.identifier.spage725
dc.identifier.urihttp://hdl.handle.net/10722/164364
dc.identifier.volume46
dc.languageeng
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.jcge.com
dc.publisher.placeUnited States
dc.relation.ispartofJournal of Clinical Gastroenterology
dc.relation.referencesReferences in Scopus
dc.subjectbesifovir
dc.subjectFG-3019
dc.subjectHELIPSAV
dc.subjectinterferon-λ
dc.subjectREP 9AC
dc.subjectvaccination
dc.titleFuture prevention and treatment of chronic hepatitis B infection
dc.typeArticle
Author Affiliations
  1. The University of Hong Kong